Lobbying registration dated 2026-03-16
Registrant: Bettina Hamelin
Client: Innovative Medicines Canada
Targeted institutions:
Canadian Institutes of Health Research (CIHR)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Global Affairs Canada (GAC)
Canadian International Trade Tribunal (CITT)
Patented Medicine Prices Review Board (PMPRB)
Justice Canada (JC)
Finance Canada (FIN)
House of Commons
National Defence (DND)
Natural Resources Canada (NRCan)
Statistics Canada (StatCan)
Employment and Social Development Canada (ESDC)
Agriculture and Agri-Food Canada (AAFC)
Veterans Affairs Canada (VAC)
National Research Council (NRC)
Canada Revenue Agency (CRA)
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Natural Sciences and Engineering Research Council (NSERC)
Health Canada (HC)
Competition Tribunal (CT)
Environment and Climate Change Canada (ECCC)
Prime Minister's Office (PMO)
Fisheries and Oceans Canada (DFO)
Innovation, Science and Economic Development Canada (ISED)
Acts: Patent Act
Food and Drugs Act
Income Tax Act
Government funding received:
Lobbying activity details:
Activities related to the Convention on Biological Diversity (CBD) including Digital Sequence Information (DSI) and an Access and Benefit Sharing (ABS) framework.
World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
National Strategy for Drugs for Rare Diseases
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Income Tax Act as it relates to biopharmaceutical products
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
Free trade agreements as they relate to the biopharmaceutical industry
Proposed pharmacare legislation related to any future national pharmacare program
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
World Health Organization (WHO) issues concerning the biopharmaceutical industry